Novartis’ fourth-quarter profits have leapt 62%, but the firm’s stock has still fallen this morning as the figures missed analyst estimates.

Net income came in at just over $1.5 billion, though the like, year-earlier figures were hit by restructuring charges. Sales edged up 1%, hit by “the severe negative impact of volatile currency markets” to $10.01 billion.

Pharmaceutical revenues were up 5% to $6.43 billion, driven by the blood pressure lowerer Diovan (valsartan), where sales increased 5% to $1.42 billion, while Glivec/Gleevec (imatinib), for chronic myeloid leukaemia and gastrointestinal stromal tumours, also rose 5% to $890 million.

Sales of Femara (letrozole), for women with hormone-sensitive breast cancer, were up 8% to $279 million and Zometa (zoledronic acid) for cancer complications, brought in $345 million, up 1%. Turnover of the acromegaly therapy Sandostatin (ocreotide) slipped 3% to $271 million.

As for Novartis’ newer products, the cardiovascular drug Exforge (amlodipine plus valsartan) brought in $118 million, up 131%, while Exjade (deferasirox), the first once-daily oral therapy for treating patients with iron overload, soared 42% to $145 million. Lucentis (ranibizumab) for the treatment of age-related macular degeneration shot up 34% to $228 million. The effect of patent expiries hit sales of the epilepsy drug Trileptal (oxcarbazepine), down 57% to $86 million.

The Basel-based group also announced strong growth for its vaccines and diagnostics segment, with sales up 23% to $491 million, though revenues from the generics unit Sandoz and the consumer health division reached $1.80 billion and $1.35 billion, down 8% and 4% respectively.

At 10.40am, Novartis shares were down 3.1% to 49.86 Swiss francs.